Articles

siRNA and RNAi Sequence Listing: Patent Disclosure Best Practices

If you are filing a patent application involving RNA interference technology, understanding the siRNA sequence listing requirements is not optional. It is the foundation of a successful and defensible patent application. Whether you are a biotechnology attorney, a patent agent, or a molecular biologist stepping into the IP world for the first time, this guide will walk you through everything you need to know, in plain language, with practical clarity.

What Is siRNA and Why Does Patent Disclosure Matter?

Small interfering RNA, commonly known as siRNA, is a class of double-stranded RNA molecules typically 20 to 25 nucleotides in length. These molecules play a central role in the RNA interference (RNAi) pathway, a biological mechanism that silences or “knocks down” the expression of specific genes by degrading target messenger RNA (mRNA).

Since the Nobel Prize-winning discovery of RNAi by Andrew Fire and Craig Mello in 2006, the pharmaceutical and biotechnology industries have invested heavily in siRNA-based therapeutics. Drugs like Patisiran (Onpattro) and Inclisiran have already received regulatory approval, signaling that siRNA is no longer experimental. It is a commercial reality.

This makes patent protection critically important. But protecting siRNA inventions requires precise and compliant sequence disclosures. Errors in sequence listing submissions can result in patent application abandonment, loss of priority dates, or invalidation during litigation. This is why siRNA sequence listing requirements must be taken seriously from day one of your patent drafting process.

Understanding WIPO ST.26 and Its Impact on siRNA Filings

The most significant recent development in patent sequence listing standards is the transition from WIPO Standard ST.25 to WIPO Standard ST.26. This transition became mandatory on July 1, 2022, for all major patent offices including the USPTO, EPO, JPO, and CNIPA.

For siRNA inventors and patent practitioners, this transition introduced several changes that directly affect how RNA sequences must be listed and formatted.

Under ST.26, sequence listings must be submitted in XML format using the WIPO Sequence software. This replaces the older plain-text (.txt) format used under ST.25. The shift is not merely cosmetic. It changes how sequences are identified, annotated, and cross-referenced within the application.

Key changes under ST.26 relevant to siRNA filings include:

RNA must now be listed as RNA, not DNA. Under ST.25, it was common practice to represent RNA sequences using DNA notation (replacing uracil “U” with thymine “T”). Under ST.26, RNA sequences must be disclosed using RNA notation, with uracil represented as “U”. This is a critical distinction for siRNA, since both the guide strand and the passenger strand are RNA molecules.
Modified nucleotides must be explicitly annotated. siRNA therapeutics frequently use chemical modifications, such as 2′-O-methyl, phosphorothioate linkages, or locked nucleic acids (LNA), to improve stability and reduce immunogenicity. ST.26 requires that each modified residue be individually annotated using standardized feature keys and qualifiers.
Both strands of a duplex must be disclosed separately. A siRNA molecule is double-stranded, consisting of a guide strand (antisense) and a passenger strand (sense). Each strand must be listed as a separate sequence entry with its own SEQ ID NO.
Sequences shorter than 10 nucleotides are excluded. If your siRNA design includes very short oligonucleotides or overhangs below 10 nucleotides, those fragments may not qualify as listable sequences under ST.26 rules.

Core siRNA Sequence Listing Requirements Every Applicant Must Know

Meeting the siRNA sequence listing requirements is a multi-layered process. It involves biological accuracy, legal precision, and software compliance. Below is a concentrated breakdown of the most essential requirements you must address in every siRNA patent application.

Sequence Identification and Numbering

Every sequence in the listing must have a unique SEQ ID NO assigned in the order they appear in the application. The claims, description, and drawings must consistently refer to sequences using their assigned SEQ ID NO. For siRNA applications with multiple candidates or variants, this means maintaining a master list and cross-checking every mention throughout the document.

Organism and Molecule Type Annotation

Each sequence entry must include the correct molecule type. For siRNA, this is typically listed as “RNA” or “other RNA” if heavily modified. The source organism field must be filled in accurately. For synthetic siRNA molecules that do not occur naturally, the organism field should reflect “synthetic construct” or “artificial sequence” as appropriate, with a feature annotation explaining the synthetic nature.

Disclosure of Chemical Modifications

This is where many siRNA patent applications fall short. Therapeutic siRNA molecules are rarely unmodified. The full siRNA sequence listing requirements under ST.26 mandate that every non-standard linkage or modified nucleotide be disclosed at the exact position within the sequence. Failing to disclose modifications accurately can affect both patentability and enforceability of the claims.

Best Practices for Drafting RNAi Patent Applications

Getting the science right is only half the challenge. The other half is making sure your patent application is drafted in a way that maximizes protection and survives examination. Here are best practices that experienced patent practitioners follow when handling RNAi inventions.

Start sequence listing preparation early. Do not treat the sequence listing as an afterthought. Many applicants draft the claims and description first, then struggle to reconcile them with the sequence listing. The better approach is to build the sequence listing in parallel with the specification.

Use WIPO Sequence software from the beginning. The WIPO Sequence tool is freely available and is the only software that generates ST.26-compliant XML files accepted by major patent offices. Starting your listing in this tool avoids reformatting headaches later.

Validate your XML file before submission. The WIPO Sequence software includes a built-in validation function. Always run validation before submitting. Common errors include missing feature annotations, incorrect molecule type designations, and mismatched SEQ ID NOs between the specification and the listing.

Work with a sequence listing specialist. Many law firms and biotech companies now employ dedicated sequence listing specialists who work alongside patent attorneys. For complex siRNA applications with dozens of modified sequences, this collaboration is not a luxury. It is a practical necessity.

Claim both strands and the duplex. Strong siRNA patent claims typically cover the guide strand individually, the passenger strand individually, and the double-stranded duplex as a whole. This layered claim strategy provides broader protection and makes it harder for competitors to design around your patent.

Consider including functional variants in your claims. siRNA sequences with one or two nucleotide mismatches may still exhibit potent gene silencing activity. Disclosing and claiming these variants, supported by experimental data, can significantly broaden your patent protection.

Common Mistakes That Lead to Rejection or Invalidation

Understanding what goes wrong in siRNA patent filings is just as important as knowing what to do right. Several recurring mistakes surface repeatedly in patent examination and post-grant proceedings.

Using DNA notation for RNA sequences is still one of the most common errors seen in siRNA filings, particularly in applications prepared before the ST.26 transition but filed after the deadline. Patent offices will issue a notice requiring correction, and in some jurisdictions, failure to correct in time can result in the sequence listing being disregarded entirely.

Incomplete modification disclosure is another frequent issue. If a siRNA drug candidate relies on a specific pattern of chemical modifications for its therapeutic efficacy, and those modifications are not fully disclosed in the sequence listing, competitors may be able to argue that the patent does not sufficiently support the claims.

Failure to list all sequences referenced in the claims also causes problems. Every sequence that is identified by a specific structure in the claims must appear in the sequence listing with a proper SEQ ID NO. If a claim refers to a sequence but that sequence is missing from the listing, the claim may be rejected for lack of written description support.

Navigating International Filing Considerations

siRNA inventions are often filed internationally through the Patent Cooperation Treaty (PCT) system. The siRNA sequence listing requirements under a PCT application must comply with ST.26 and must be submitted as part of the international application.

When entering national or regional phases, applicants must confirm that the sequence listing format meets the requirements of each jurisdiction. Most major patent offices now mandate ST.26 compliance, but there are nuances. Some offices may require translation of sequence listing annotations, while others may have specific local requirements for how organism names or modification features are described.

For applicants filing in China, Japan, Europe, and the United States simultaneously, coordinating the sequence listing across all these filings requires careful version control and jurisdiction-specific review.

Conclusion: Precision Is Protection

In the world of siRNA and RNAi patents, precision in sequence disclosure is not a bureaucratic formality. It is the backbone of your intellectual property protection. Meeting the siRNA sequence listing requirements correctly ensures that your patent application moves through examination smoothly, your claims hold up during licensing negotiations, and your patent survives challenge.

As siRNA therapeutics continue to advance from research pipelines into approved medicines, the value of a well-drafted, fully compliant patent application will only grow. Invest the time, use the right tools, work with specialists who understand both the science and the legal requirements, and treat your sequence listing with the same rigor you apply to your laboratory data.

The difference between a strong siRNA patent and a weak one often comes down to how accurately and completely the sequences were disclosed from the very beginning.

We are the leading Patent Sequence Listing Company

At our Sequence Listing Company, we specialize exclusively in creating perfect patent sequence listings for biotechnology and pharmaceutical companies. Founded by patent attorneys and bioinformatics specialists with over 10 years of experience, we understand the critical intersection of scientific innovation and intellectual property protection. Our dedicated team has helped hundreds of companies successfully navigate the complex regulatory requirements of sequence listings across global patent offices. We combine technical precision with regulatory expertise to ensure your valuable innovations receive the protection they deserve without delays or complications.

Our Expertise

Specialized expertise in WIPO ST.25 and ST.26 standards
Customized solutions for complex biological sequences
Guaranteed compliance with patent office requirements
Rapid 24-48 hour turnaround time
Comprehensive quality assurance process

Trust Your Patent Sequence Listings to the Industry's Leading Experts

Effectual Knowledge Services pvt. ltd.

Effectual Services is an award-winning Intellectual Property (IP) management advisory & Consulting firm.